Related Experiment Video

Updated: Apr 19, 2026

A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines
06:59

A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines

Published on: June 22, 2022

2.8K

Targeting ENaC as a Molecular Suspect in Cystic Fibrosis

Nadine Bangel-Ruland1, Katja Tomczak, Wolf-Michael Weber

  • 1Institute of Animal Physiology, Westphalian Wilhelms-University Muenster, Schlossplatz 8, D-48143 Muenster, Germany. n.br@uni-muenster.de.

Current Drug Targets
|December 30, 2014
PubMed

Insights

Cystic fibrosis (CF) lung disease involves airway dehydration due to enhanced sodium (Na+) absorption via the epithelial sodium channel (ENaC). Blocking ENaC, alongside restoring chloride (Cl-) secretion, offers a dual therapeutic strategy for CF.

Area of Science:

  • Pulmonary Medicine
  • Genetics
  • Molecular Biology

Background:

  • Cystic fibrosis (CF) is a common inherited disorder causing life-shortening lung disease.
  • Airway dehydration in CF results from excessive sodium (Na+) hyperabsorption through the epithelial sodium channel (ENaC).
  • The interplay between CFTR dysfunction and ENaC activity in CF pathogenesis is not fully understood.

Purpose of the Study:

  • To explore potential CFTR and ENaC interactions in cystic fibrosis.
  • To review the structure of ENaC and methods to inhibit Na+ hyperabsorption in CF lung disease.
  • To summarize existing therapies and novel approaches for blocking ENaC.

Main Methods:

  • Review of scientific literature on CFTR and ENaC.
  • Discussion of ENaC structure and function.
  • Analysis of therapeutic strategies including amiloride, antisense oligonucleotides (ASOs), and small interfering RNA (siRNA).

Main Results:

  • Reduced chloride (Cl-) secretion by defective CFTR and enhanced Na+ absorption via ENaC contribute to CF.
  • Various therapeutic strategies aim to restore Cl- secretion or block Na+ hyperabsorption.
  • ASOs and siRNA show promise for inhibiting ENaC and reducing Na+ hyperabsorption.

Conclusions:

  • A dual therapeutic approach targeting both CFTR and ENaC is a promising strategy for CF.
  • Inhibiting ENaC offers a viable method to counteract airway dehydration in CF.
  • Novel approaches like ASOs and siRNA present innovative ways to block ENaC in CF lung disease.

More Related Videos

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

8.3K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
656
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72